Numbers and rates of adverse events of interest with tumour necrosis factor inhibitor treatment in patients with any adalimumab exposure (N=311, 1201.1 patient-years)
| N (E/100 PYs) | |
|---|---|
| Serious adverse events | 140 (11.7) |
| Serious infections | 17 (1.4) |
| Opportunistic infections* | 12 (1.0) |
| Malignancies (excluding lymphoma and NMSC) | 3 (0.2) |
| Lymphoma | 1 (<0.1) |
| NMSC | 5 (0.4) |
| Lupus-like syndrome | 1 (<0.1) |
| Congestive heart failure-related | 2 (0.2) |
E, events; NMSC, non-melanoma skin cancer; PYs, patient-years.
↵* All mild to moderate candidiasis